Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Share :
Published: 3 Jun 2012
Views: 4258
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Kimberly Blackwell presented on a phase III randomised study, EMILIA, of the investigational agent trastuzumab emtansine (T-DM1) vs. standard therapy using capecitabine and lapatinib.


Dr Blackwell and her team found significant and clinically meaningful improvement in progression-free survival with T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab.